On October 29, 2021, Watson Bio disclosed its third quarterly report that the company achieved a total operating income of 2.13 billion yuan in the first three quarters of 2021, an increase of 35.9% year-on-year; a net profit attributable to the mother of 360 million yuan, down 16.3% year-on-year; and earnings per share of 0.23 yuan.
Note: Watson Bio completed a major asset restructuring on December 21, 2016.
Expense ratio increased by 4.2% and operating cash flow increased by 135.1% during the period
The company's operating costs in the third quarter of 2021 were 270 million, an increase of 25.7% year-on-year, lower than the growth rate of 35.9% in operating income, resulting in a 1% increase in gross profit margin. The expense ratio for the period was 59.7 per cent, an increase of 4.2 per cent over the previous year. Operating cash flow rose significantly by 135.1% to 270 million.
Disclaimer: This article is based on big data production, for reference only, does not constitute any investment advice, and operates accordingly at your own risk.